ipragliflozin
Sign in to saveAlso known as C21H21FO5S
Ipragliflozin (INN, trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, and in Russia on May 22, 2019.
~6 min read
Encyclopedic overview
5 sectionsContents
- Clinical trials
- Commercialization
- Marketing
- Intellectual Property
- References
{{Infobox drug | drug_name = | IUPAC_name = (2S,3R,4R,5S,6R)-2-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-6-(hydroxymethyl)oxane-3,4,5-triol | image = Ipragliflozin structure.svg | image_class = skin-invert-image | width = 275 | image2 = Haworth projection of ipragliflozin.svg | image_class2 = skin-invert-image | width2 = 225 | caption = Haworth projection (bottom)
| tradename = Suglat | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_AU_comment = | legal_CA = | legal_NZ = | legal_UK = | legal_US_comment = Not available | legal_UN = | legal_status = Rx-only (JP) | routes_of_administration = By mouth (tablets)
Excerpted from Wikipedia’s “ipragliflozin” article, available under the CC BY-SA 4.0 licence.